TG Therapeutics (TGTX) Institutional Ownership

58.58% of TG Therapeutics' stock is owned by institutional investors. Learn more on TGTX's institutional investor holdings.

Of the 345 institutional investors that purchased TG Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: State Street Corp ($2.96M), Marshall Wace LLP ($2.05M), Congress Asset Management Co. ($1.92M), Clearbridge Investments LLC ($1.84M), Principal Financial Group Inc. ($1.53M), Raymond James Financial Inc. ($1.17M), and Wellington Management Group LLP ($1.16M).

Institutional investors have bought a total of 17,533,796 shares in the last 24 months. This purchase volume represents approximately $570.21M in transactions.

Of the 140 institutional investors that sold TG Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: 1832 Asset Management L.P. ($1.34M), Soleus Capital Management L.P. ($1.31M), Clearbridge Investments LLC ($1.20M), BNP Paribas Financial Markets ($479.57K), Royal Bank of Canada ($418.97K), Price T Rowe Associates Inc. MD ($352.53K), and Millennium Management LLC ($324.85K).

Institutional investors have sold a total of 9,336,310 shares in the last 24 months. This volume of shares sold represents approximately $311.09M in transactions.